心臓アミロイドーシスの世界市場レポート 2025年

心臓アミロイドーシス市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は9.0%で81億米ドルに成長します。予測期間中の成長は、診断率の上昇、政府の支援とイニシアチブ、遺伝子変異の有病率の上昇、患者支援プログラムに起因すると考えられます。この期間に予想される主な動向には、ブトリシランなどの新規治療法の開発、遺伝子治療研究の拡大、精密医療への注力、診断技術の進歩、新規治療の出現などがあります。

老年人口の増加は、今後数年間の心臓アミロイドーシス市場の成長を牽引すると予想されます。老年人口とは、65歳以上の高齢者を指し、加齢に関連した疾患のために専門的なヘルスケアを必要とすることが多いです。この人口が着実に増加している背景には、平均寿命の伸び、医療の進歩、出生率の低下があります。加齢は心臓にアミロイド蛋白が蓄積する重大な危険因子であるため、高齢者の増加は心臓アミロイドーシスの有病率の増加に寄与しています。例えば、米国の非営利団体である人口問題研究所によると、米国の65歳以上の人口は2022年の5,800万人から2050年には8,200万人へと47％増加すると予測されています。その結果、老年人口層の拡大が心臓アミロイドーシス市場の成長を促進すると予想されます。

心臓アミロイドーシス市場の主要企業は、人工知能（AI）ベースの診断ツールなどの技術的進歩に注力し、疾患の早期発見と臨床転帰の向上に努めています。AIを搭載したソフトウェアのみの医療機器は、追加のハードウェアや広範な臨床データを必要とすることなく、心エコー画像を分析し、心臓アミロイドーシスの兆候を特定することができます。例えば、2024年11月、英国の医療技術企業であるUltromics Ltd.は、早期心臓アミロイドーシス検出のためのAI駆動型臨床ツールであるEchoGo AmyloidosisのFDA認可を確保しました。これは、FDAのTotal Product Lifecycle Advisory Program（TAP）において、初めて販売許可を取得した機器です。AIを活用したEchoGo Amyloidosisは、1つのクリップから心エコーを解析し、病気が発見されないまま進行する前に早期発見を可能にします。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界心臓アミロイドーシス PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の心臓アミロイドーシス市場：成長率分析
• 世界の心臓アミロイドーシス市場の実績：規模と成長, 2019-2024
• 世界の心臓アミロイドーシス市場の予測：規模と成長, 2024-2029, 2034F
• 世界心臓アミロイドーシス総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の心臓アミロイドーシス市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 軽鎖アミロイドーシス
• トランスサイレチンアミロイドーシス
• 世界の心臓アミロイドーシス市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 手術
• 支持療法
• 幹細胞移植
• 標的療法
• 世界の心臓アミロイドーシス市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 外来手術センター
• クリニック
• 世界の心臓アミロイドーシス市場軽鎖アミロイドーシスのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫グロブリン軽鎖（AL）アミロイドーシス
• 原発性軽鎖アミロイドーシス
• 二次性軽鎖アミロイドーシス
• 世界の心臓アミロイドーシス市場トランスサイレチンアミロイドーシスの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝性トランスサイレチンアミロイドーシス（ATTRm）
• 野生型トランスサイレチンアミロイドーシス（ATTRwt）

第7章 地域別・国別分析

• 世界の心臓アミロイドーシス市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の心臓アミロイドーシス市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 心臓アミロイドーシス市場：競合情勢
• 心臓アミロイドーシス市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novo Nordisk A/S
• Alexion Pharmaceuticals Inc.
• Dr. Reddy's Laboratories
• Alnylam Pharmaceuticals Inc.
• Ionis Pharmaceuticals Inc.
• Akcea Therapeutics Inc.
• BridgeBio Pharma Inc.
• Prothena Corp
• Intellia Therapeutics Inc.
• Amylyx Pharmaceuticals
• Neurimmune AG
• SOM Biotech
• Oncopeptides
• Attralus Inc.
• Eidos Therapeutics

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 心臓アミロイドーシス市場2029：新たな機会を提供する国
• 心臓アミロイドーシス市場2029：新たな機会を提供するセグメント
• 心臓アミロイドーシス市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Cardiac amyloidosis is a condition characterized by the deposition of abnormal amyloid proteins in the heart tissue, resulting in stiffness and impaired function. This leads to heart failure, arrhythmias, and other cardiovascular complications. Early diagnosis and treatment are essential for managing symptoms and slowing disease progression.

The primary types of cardiac amyloidosis are light-chain amyloidosis and transthyretin amyloidosis. Light-chain amyloidosis (AL amyloidosis) is a disorder in which misfolded immunoglobulin light chains form amyloid deposits in various organs, including the heart, causing dysfunction and potential organ failure. Treatment options include chemotherapy, surgery, supportive care, stem cell transplantation, and targeted therapy. The disease is primarily managed in hospitals, ambulatory surgical centers, and clinics.

The cardiac amyloidosis market research report is one of a series of new reports from The Business Research Company that provides cardiac amyloidosis market statistics, including the cardiac amyloidosis industry global market size, regional shares, competitors with the cardiac amyloidosis market share, detailed cardiac amyloidosis market segments, market trends, and opportunities, and any further data you may need to thrive in the cardiac amyloidosis industry. This cardiac amyloidosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cardiac amyloidosis market size has grown strongly in recent years. It will grow from $5.26 billion in 2024 to $5.75 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. The growth during the historic period can be attributed to the increasing prevalence of amyloidosis-related conditions, genetic mutations, heightened awareness, a rising number of transthyretin amyloidosis cases, and the growing geriatric population.

The cardiac amyloidosis market size is expected to see strong growth in the next few years. It will grow to $8.10 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth during the forecast period can be attributed to higher diagnosis rates, government support and initiatives, the rising prevalence of genetic mutations, and patient assistance programs. Key trends expected in this period include the development of new therapies such as vutrisiran, expanding research in gene therapy, a focus on precision medicine, advancements in diagnostic technologies, and the emergence of novel treatments.

The rising geriatric population is expected to drive the growth of the cardiac amyloidosis market in the coming years. The geriatric population refers to individuals aged 65 and older who often require specialized healthcare due to age-related conditions. The steady increase in this population is driven by rising life expectancy, advancements in medical care, and declining birth rates. Since aging is a significant risk factor for amyloid protein accumulation in the heart, the growing number of older adults contributes to the increasing prevalence of cardiac amyloidosis. For example, according to the Population Reference Bureau, a US-based nonprofit organization, the US population aged 65 and older is projected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. As a result, the expanding geriatric demographic is expected to fuel the growth of the cardiac amyloidosis market.

Leading companies in the cardiac amyloidosis market are focusing on technological advancements, such as artificial intelligence (AI)-based diagnostic tools, to improve early disease detection and enhance clinical outcomes. AI-powered, software-only medical devices can analyze echocardiographic images and identify signs of cardiac amyloidosis without the need for additional hardware or extensive clinical data. For instance, in November 2024, Ultromics Ltd., a UK-based health technology company, secured FDA clearance for EchoGo Amyloidosis, an AI-driven clinical tool for early cardiac amyloidosis detection. It is the first device in the FDA's Total Product Lifecycle Advisory Program (TAP) to receive marketing authorization. Using AI, EchoGo Amyloidosis analyzes echocardiograms from a single clip, enabling earlier detection before the disease progresses undetected.

In January 2024, Ultromics Ltd. partnered with Pfizer Inc. to further develop its Echo AI algorithm for cardiac amyloidosis detection. This partnership aims to enhance diagnostic accuracy and improve patient outcomes. Pfizer Inc. is a US-based pharmaceutical company specializing in innovative medicines, including treatments for cardiac amyloidosis, as well as consumer healthcare products.

Major players in the cardiac amyloidosis market are Pfizer Inc., Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Alexion Pharmaceuticals Inc., Dr. Reddy's Laboratories, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., BridgeBio Pharma Inc., Prothena Corp, Intellia Therapeutics Inc., Amylyx Pharmaceuticals, Neurimmune AG, SOM Biotech, Oncopeptides, Attralus Inc., and Eidos Therapeutics.

North America was the largest region in the cardiac amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cardiac amyloidosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cardiac amyloidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cardiac amyloidosis market consists of revenues earned by entities by providing services such as early diagnosis through imaging and biomarker testing, medication management, and supportive therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiac amyloidosis market also includes sales of diagnostic imaging tools, biomarker testing kits, and disease-modifying therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cardiac Amyloidosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cardiac amyloidosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cardiac amyloidosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cardiac amyloidosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Light Chain Amyloidosis; Transthyretin Amyloidosis
• 2) By Treatment: Chemotherapy; Surgery; Supportive Care; Stem Cell Transplant; Targeted Therapy
• 3) By End-User: Hospitals; Ambulatory Surgical Centres; Clinics
• Subsegments:
• 1) By Light Chain Amyloidosis: Immunoglobulin Light Chain (AL) Amyloidosis; Primary Light Chain Amyloidosis; Secondary Light Chain Amyloidosis
• 2) By Transthyretin Amyloidosis: Hereditary Transthyretin Amyloidosis (ATTRm); Wild-type Transthyretin Amyloidosis (ATTRwt)
• Companies Mentioned: Pfizer Inc.; Sanofi S.A.; AstraZeneca plc; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cardiac Amyloidosis Market Characteristics

3. Cardiac Amyloidosis Market Trends And Strategies

4. Cardiac Amyloidosis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Cardiac Amyloidosis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cardiac Amyloidosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cardiac Amyloidosis Market Growth Rate Analysis
• 5.4. Global Cardiac Amyloidosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cardiac Amyloidosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cardiac Amyloidosis Total Addressable Market (TAM)

6. Cardiac Amyloidosis Market Segmentation

• 6.1. Global Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Light Chain Amyloidosis
• Transthyretin Amyloidosis
• 6.2. Global Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Surgery
• Supportive Care
• Stem Cell Transplant
• Targeted Therapy
• 6.3. Global Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ambulatory Surgical Centres
• Clinics
• 6.4. Global Cardiac Amyloidosis Market, Sub-Segmentation Of Light Chain Amyloidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunoglobulin Light Chain (AL) Amyloidosis
• Primary Light Chain Amyloidosis
• Secondary Light Chain Amyloidosis
• 6.5. Global Cardiac Amyloidosis Market, Sub-Segmentation Of Transthyretin Amyloidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hereditary Transthyretin Amyloidosis (ATTRm)
• Wild-type Transthyretin Amyloidosis (ATTRwt)

7. Cardiac Amyloidosis Market Regional And Country Analysis

• 7.1. Global Cardiac Amyloidosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cardiac Amyloidosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cardiac Amyloidosis Market

• 8.1. Asia-Pacific Cardiac Amyloidosis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cardiac Amyloidosis Market

• 9.1. China Cardiac Amyloidosis Market Overview
• 9.2. China Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cardiac Amyloidosis Market

• 10.1. India Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cardiac Amyloidosis Market

• 11.1. Japan Cardiac Amyloidosis Market Overview
• 11.2. Japan Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cardiac Amyloidosis Market

• 12.1. Australia Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cardiac Amyloidosis Market

• 13.1. Indonesia Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cardiac Amyloidosis Market

• 14.1. South Korea Cardiac Amyloidosis Market Overview
• 14.2. South Korea Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cardiac Amyloidosis Market

• 15.1. Western Europe Cardiac Amyloidosis Market Overview
• 15.2. Western Europe Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cardiac Amyloidosis Market

• 16.1. UK Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cardiac Amyloidosis Market

• 17.1. Germany Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cardiac Amyloidosis Market

• 18.1. France Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cardiac Amyloidosis Market

• 19.1. Italy Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cardiac Amyloidosis Market

• 20.1. Spain Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cardiac Amyloidosis Market

• 21.1. Eastern Europe Cardiac Amyloidosis Market Overview
• 21.2. Eastern Europe Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cardiac Amyloidosis Market

• 22.1. Russia Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cardiac Amyloidosis Market

• 23.1. North America Cardiac Amyloidosis Market Overview
• 23.2. North America Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cardiac Amyloidosis Market

• 24.1. USA Cardiac Amyloidosis Market Overview
• 24.2. USA Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cardiac Amyloidosis Market

• 25.1. Canada Cardiac Amyloidosis Market Overview
• 25.2. Canada Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cardiac Amyloidosis Market

• 26.1. South America Cardiac Amyloidosis Market Overview
• 26.2. South America Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cardiac Amyloidosis Market

• 27.1. Brazil Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cardiac Amyloidosis Market

• 28.1. Middle East Cardiac Amyloidosis Market Overview
• 28.2. Middle East Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cardiac Amyloidosis Market

• 29.1. Africa Cardiac Amyloidosis Market Overview
• 29.2. Africa Cardiac Amyloidosis Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cardiac Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cardiac Amyloidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cardiac Amyloidosis Market Competitive Landscape And Company Profiles

• 30.1. Cardiac Amyloidosis Market Competitive Landscape
• 30.2. Cardiac Amyloidosis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

31. Cardiac Amyloidosis Market Other Major And Innovative Companies

• 31.1. Novo Nordisk A/S
• 31.2. Alexion Pharmaceuticals Inc.
• 31.3. Dr. Reddy's Laboratories
• 31.4. Alnylam Pharmaceuticals Inc.
• 31.5. Ionis Pharmaceuticals Inc.
• 31.6. Akcea Therapeutics Inc.
• 31.7. BridgeBio Pharma Inc.
• 31.8. Prothena Corp
• 31.9. Intellia Therapeutics Inc.
• 31.10. Amylyx Pharmaceuticals
• 31.11. Neurimmune AG
• 31.12. SOM Biotech
• 31.13. Oncopeptides
• 31.14. Attralus Inc.
• 31.15. Eidos Therapeutics

32. Global Cardiac Amyloidosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cardiac Amyloidosis Market

34. Recent Developments In The Cardiac Amyloidosis Market

35. Cardiac Amyloidosis Market High Potential Countries, Segments and Strategies

• 35.1 Cardiac Amyloidosis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cardiac Amyloidosis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cardiac Amyloidosis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer